Combined detection of homocysteine and hypersensitive c-reactive protein in the risk assessment of coronary heart disease

Objective: The goal of this study was to determine the clinical value of combined detection of homocysteine (Hcy) and hypersensitive C-reactive protein (hs-CRP) in risk assessment of coronary heart disease (CHD). Methods: A total of 182 patients with CHD were enrolled as the CHD group, and 213 healthy people who came to Shenzhen Bao'an Hospital of Traditional Chinese Medicine (Group) for physical examination during the same period were selected as the control group. Baseline data for both groups were analyzed retrospectively, including gender, age, body mass index, systolic blood pressure, diastolic blood pressure, triglyceride, total cholesterol, blood glucose, smoking history, and drinking history. The venous plasma parameters of the two groups such as red blood cells, white blood cells, platelets, low density lipoprotein, uric acid, Hcy and hs-CRP were compared. ROC curve and logistic regression analysis were used to evaluate the results. Results: The baseline data of the two groups were equally comparable (P > 0.05). Compared with the control group, the levels of white blood cells, low density lipoprotein, uric acid, Hcy and hs-CRP in the CHD group were significantly increased (all P < 0.05). Multivariate logistic regression analysis indicated that low density lipoprotein, Hcy and hs-CRP were independent risk factors for CHD (P < 0.05). The area under the ROC curve of the serum Hcy level was 0.791 while the hs-CRP was 0.850, and the combined detection of the two was 0.946. The specificity (85%) and sensitivity (97%) of Hcy combined with hs-CRP detection were better than the single detection, and the differences were statistically significant (P < 0.05). Conclusion: Serum Hcy and hs-CRP levels are closely related to CHD. Combined detection of Hcy and hs-CRP can be used as an important indicator for clinical risk assessment of patients with CHD, thereby providing a basis for clinical early diagnosis and contributing to the improvement of the prevention, treatment and prognosis of CHD.